|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARHGAP6 |
Gene summary for ARHGAP6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARHGAP6 | Gene ID | 395 |
| Gene name | Rho GTPase activating protein 6 | |
| Gene Alias | RHOGAP6 | |
| Cytomap | Xp22.2 | |
| Gene Type | protein-coding | GO ID | GO:0001952 | UniProtAcc | O43182 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 395 | ARHGAP6 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 1.09e-02 | -1.26e-01 | 0.02 |
| 395 | ARHGAP6 | male-WTA | Human | Thyroid | PTC | 8.36e-16 | 5.75e-02 | 0.1037 |
| 395 | ARHGAP6 | PTC01 | Human | Thyroid | PTC | 6.99e-03 | 2.15e-02 | 0.1899 |
| 395 | ARHGAP6 | PTC04 | Human | Thyroid | PTC | 1.03e-05 | 5.03e-02 | 0.1927 |
| 395 | ARHGAP6 | PTC05 | Human | Thyroid | PTC | 8.40e-06 | 2.29e-01 | 0.2065 |
| 395 | ARHGAP6 | PTC06 | Human | Thyroid | PTC | 6.76e-11 | 4.92e-01 | 0.2057 |
| 395 | ARHGAP6 | PTC07 | Human | Thyroid | PTC | 3.60e-14 | 2.69e-01 | 0.2044 |
| 395 | ARHGAP6 | ATC12 | Human | Thyroid | ATC | 1.09e-02 | -1.38e-01 | 0.34 |
| 395 | ARHGAP6 | ATC13 | Human | Thyroid | ATC | 3.78e-15 | 3.37e-01 | 0.34 |
| 395 | ARHGAP6 | ATC2 | Human | Thyroid | ATC | 3.39e-03 | 2.66e-01 | 0.34 |
| 395 | ARHGAP6 | ATC5 | Human | Thyroid | ATC | 1.15e-14 | 3.72e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190290318 | Prostate | BPH | regulation of supramolecular fiber organization | 133/3107 | 383/18723 | 2.40e-18 | 8.73e-16 | 133 |
| GO:000701518 | Prostate | BPH | actin filament organization | 147/3107 | 442/18723 | 3.36e-18 | 1.15e-15 | 147 |
| GO:003297018 | Prostate | BPH | regulation of actin filament-based process | 133/3107 | 397/18723 | 7.07e-17 | 1.62e-14 | 133 |
| GO:003295618 | Prostate | BPH | regulation of actin cytoskeleton organization | 118/3107 | 358/18723 | 1.51e-14 | 1.87e-12 | 118 |
| GO:015011515 | Prostate | BPH | cell-substrate junction organization | 49/3107 | 101/18723 | 9.49e-14 | 1.01e-11 | 49 |
| GO:005101718 | Prostate | BPH | actin filament bundle assembly | 65/3107 | 157/18723 | 1.31e-13 | 1.38e-11 | 65 |
| GO:011005318 | Prostate | BPH | regulation of actin filament organization | 96/3107 | 278/18723 | 1.90e-13 | 1.89e-11 | 96 |
| GO:006157218 | Prostate | BPH | actin filament bundle organization | 65/3107 | 161/18723 | 5.29e-13 | 4.75e-11 | 65 |
| GO:000704410 | Prostate | BPH | cell-substrate junction assembly | 46/3107 | 95/18723 | 5.89e-13 | 5.21e-11 | 46 |
| GO:005125818 | Prostate | BPH | protein polymerization | 96/3107 | 297/18723 | 1.52e-11 | 1.10e-09 | 96 |
| GO:003158910 | Prostate | BPH | cell-substrate adhesion | 110/3107 | 363/18723 | 4.64e-11 | 2.96e-09 | 110 |
| GO:015011615 | Prostate | BPH | regulation of cell-substrate junction organization | 35/3107 | 71/18723 | 1.81e-10 | 1.02e-08 | 35 |
| GO:001081017 | Prostate | BPH | regulation of cell-substrate adhesion | 74/3107 | 221/18723 | 5.40e-10 | 2.70e-08 | 74 |
| GO:00072658 | Prostate | BPH | Ras protein signal transduction | 101/3107 | 337/18723 | 5.64e-10 | 2.79e-08 | 101 |
| GO:00480419 | Prostate | BPH | focal adhesion assembly | 39/3107 | 87/18723 | 6.07e-10 | 2.91e-08 | 39 |
| GO:000815416 | Prostate | BPH | actin polymerization or depolymerization | 72/3107 | 218/18723 | 1.82e-09 | 7.59e-08 | 72 |
| GO:005189310 | Prostate | BPH | regulation of focal adhesion assembly | 32/3107 | 66/18723 | 1.85e-09 | 7.63e-08 | 32 |
| GO:009010910 | Prostate | BPH | regulation of cell-substrate junction assembly | 32/3107 | 66/18723 | 1.85e-09 | 7.63e-08 | 32 |
| GO:000195210 | Prostate | BPH | regulation of cell-matrix adhesion | 48/3107 | 128/18723 | 9.98e-09 | 3.34e-07 | 48 |
| GO:003003817 | Prostate | BPH | contractile actin filament bundle assembly | 42/3107 | 106/18723 | 1.27e-08 | 4.07e-07 | 42 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARHGAP6 | SNV | Missense_Mutation | novel | c.244N>C | p.Ser82Pro | p.S82P | O43182 | protein_coding | deleterious_low_confidence(0.04) | benign(0.261) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| ARHGAP6 | SNV | Missense_Mutation | c.2189N>T | p.Glu730Val | p.E730V | O43182 | protein_coding | deleterious(0) | possibly_damaging(0.677) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ARHGAP6 | SNV | Missense_Mutation | c.399N>C | p.Lys133Asn | p.K133N | O43182 | protein_coding | deleterious_low_confidence(0.04) | benign(0.193) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| ARHGAP6 | SNV | Missense_Mutation | c.952T>G | p.Phe318Val | p.F318V | O43182 | protein_coding | deleterious(0.01) | possibly_damaging(0.706) | TCGA-D8-A1XJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| ARHGAP6 | SNV | Missense_Mutation | c.2018N>T | p.Ser673Phe | p.S673F | O43182 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-E2-A1L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| ARHGAP6 | SNV | Missense_Mutation | novel | c.2072N>T | p.Gly691Val | p.G691V | O43182 | protein_coding | tolerated(0.36) | probably_damaging(0.96) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | SD | |
| ARHGAP6 | SNV | Missense_Mutation | c.998N>G | p.Ser333Cys | p.S333C | O43182 | protein_coding | deleterious(0.02) | probably_damaging(0.946) | TCGA-PE-A5DC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| ARHGAP6 | insertion | Nonsense_Mutation | novel | c.2125_2126insAGGAAGAGGAAGGTATGGCGAGCCCAGTCGTTGGCTG | p.Leu709Ter | p.L709* | O43182 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
| ARHGAP6 | SNV | Missense_Mutation | rs756253019 | c.2129N>T | p.Ser710Leu | p.S710L | O43182 | protein_coding | deleterious(0.05) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ARHGAP6 | SNV | Missense_Mutation | c.2278N>A | p.Glu760Lys | p.E760K | O43182 | protein_coding | tolerated(0.08) | benign(0.057) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |